Trial results

$IRD — OPGx-BEST1

Opus Genetics, Inc. (IRD) OPGx-BEST1: trial results in Best vitelliform macular dystrophy, 2027.

Research by Catalyst Intel

The catalyst

"Completed enrollment and dosing of 11 participants in the high-dose Cohort 2, with topline data, including 3-month data from Cohort 2 and 6-month data for the three Cohort 1 participants with Best vitelliform macular dystrophy, expected in Q1 2027."

— Opus Genetics, 8-K filed 2026-11-10 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

IRD-OPGXBEST1-2026

Company

Opus Genetics, Inc.

Kind

Trial results

Indication

Best vitelliform macular dystrophy

Window

2027-01-01 – 2027-03-31

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.